Proceeds from the placement will be used for general corporate and working capital purposes, including commercialization of the firm's ICE COLD-PCR technology.
The partners will augment the multiplexing capabilities of ICE COLD-PCR, which was developed at Dana-Farber and is exclusively licensed to Transgenomic.
Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week.
Transgenomic has completed its divestment of its Genetic Assays and Platforms unit to Adstec
The lower sales from contract laboratory services reflect Transgenomic's continued refocusing on its core ICE-COLD PCR molecular diagnostic technology.
Adstec will assume the business, financial, and human resource commitments of the business and pay Transgenomic $300,000 for stock and inventory related to the business.
The deal covers four of Transgenomic's liquid biopsy cancer assays, which detect actionable mutations associated with sensitivity or resistance to therapy.
The company sold the technology and assets to Edge BioSystems as part of an ongoing effort to divest legacy non-core businesses and product lines.
The firm has signed Spectron Scientific and Sowa Trading Company to distribute its ICEme mutation enrichment kit in China and Japan, respectively.
Adjusting for the company's third quarter 2014 sale of its Surveyor kits product line, Q2 revenue increased about 11 percent year over year.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.